Virios Therapeutics Inc
Change company Symbol lookup
Select an option...
VIRI Virios Therapeutics Inc
BOF BranchOut Food Inc
VINO Gaucho Group Holdings Inc
ONVO Organovo Holdings Inc
ZBRA Zebra Technologies Corp
BROG Brooge Energy Ltd
NTZ Natuzzi SpA
GE General Electric Co
OST Ostin Technology Group Co Ltd
CHEA Chenghe Acquisition Co
Go

Health Care : Biotechnology | Small Cap Value
Company profile

Virios Therapeutics, Inc. is a development-stage biotechnology company focused on advancing antiviral therapies to treat debilitating chronic diseases such as fibromyalgia (FM). The Company’s lead development candidate is IMC-1, which is a fixed dose combination of famciclovir, and celecoxib designed to synergistically suppress herpes virus replication. IMC-1 combines these two specific mechanisms of action purposely designed to inhibit herpes virus activation and replication. The Company’s pipeline product includes IMC-2 (valacyclovir and celecoxib), which is in the Phase 1 development stage. IMC-2 (valacyclovir and celecoxib) is developed for treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with Long-COVID or Post-Acute Sequelae of COVID-19 (PASC).

Closing Price
$0.9248
Day's Change
-0.0352 (-3.67%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.9399
Day's Low
0.8851
Volume
(Below Average)
Volume:
127,287

10-day average volume:
147,558
127,287
Latest Earnings Met Consensus (Q2 ending 06/2023)Next Earnings Announcement
Q2
Announced August 10, 2023
-$0.08Q2 Estimate range
of 2 analysts
-$0.09 to -$0.05Q3 Earnings
will announce
(Unconfirmed) November 14, 2023

Quarterly Earnings History and Estimates

Show high-low estimates
Draw trendlines

Draw up to 3 lines inside the chart.

Display:

UpdateCancel

VIRI's fiscal year ends in December

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Information provided by Copyright © 2023. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.